Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 | Q92769 | 13/20 | 0.61 |
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.61 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.61 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.61 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.61 |
| ▸ | HDAC7 | Q8WUI4 | 4/20 | 0.61 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.61 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.61 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.61 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.51 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.51 |
| ▸ | RARB | P10826 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2878907 | 0.88 | RARB (0.60) | HDAC2HDAC8HDAC6HDAC11HDAC3 | |
| SCHEMBL13310490 | 0.87 | HDAC8 (0.53) | HDAC2HDAC8HDAC6HDAC11HDAC3 | |
| SCHEMBL13067864 | 0.87 | RARB (0.47) | HDAC2HDAC8HDAC6HDAC11HDAC3 | |
| SCHEMBL13310493 | 0.84 | HDAC2 (0.64) | HDAC2HDAC8HDAC6HDAC11HDAC3 | |
| SCHEMBL13310486 | 0.79 | HDAC2 (0.44) | HDAC2HDAC8HDAC6HDAC11HDAC3 | |
| SCHEMBL3295460 | 0.76 | HDAC2 (1.00) | HDAC2HDAC8HDAC6HDAC11HDAC3 | |
| SCHEMBL3295457 | 0.76 | HDAC2 (1.00) | HDAC2HDAC8HDAC6HDAC11HDAC3 | |
| SCHEMBL13310489 | 0.75 | RARB (0.46) | HDAC2HDAC8HDAC6HDAC11HDAC3 | |
| SCHEMBL3293307 | 0.72 | HDAC2 (1.00) | HDAC2HDAC8HDAC6HDAC11HDAC3 | |
| SCHEMBL3293303 | 0.72 | HDAC2 (1.00) | HDAC2HDAC8HDAC6HDAC11HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7728039-B2 | Biphenyl and Naphthyl-Phenyl Hydroxamic Acid Derivatives | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2010-06-01 | — | — | US | disclosed |
| US-20080319082-A1 | Biphenyl and Naphthyl-Phenyl Hydroxamic Acid Derivatives | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319082-A1 | Biphenyl and Naphthyl-Phenyl Hydroxamic Acid Derivatives | VHL, ARNT, AHR | HDAC2 220/4885HDAC8 101/4885HDAC6 362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.